Literature DB >> 12580185

Initial agonist treatment of Parkinson disease: a critique.

Roger L Albin1, Kirk A Frey.   

Abstract

The evidence supporting initial dopamine agonist treatment of PD is reviewed. The two rationales for initial agonist treatment are reduced frequency of motor complications and possible relative neuroprotection by dopamine agonists. The basic science supporting these rationales is equivocal. The clinical evidence for advantages of initial agonist treatment is incomplete. More data are required to determine the optimal initial treatment for PD.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12580185     DOI： 10.1212/01.wnl.0000052681.28286.52

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

Authors:  J Eric Ahlskog; Ryan J Uitti
Journal:  Neurology       Date:  2010-04-06       Impact factor: 9.910

2.  L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.

Authors:  Jennifer M King; Gladson Muthian; Veronica Mackey; Marquitta Smith; Clivel Charlton
Journal:  Life Sci       Date:  2011-08-18       Impact factor: 5.037

Review 3.  The missing, the short, and the long: Levodopa responses and dopamine actions.

Authors:  Roger L Albin; Daniel K Leventhal
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

Review 4.  Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Authors:  Stanley Fahn
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

5.  Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release.

Authors:  Vesna Sossi; Katherine Dinelle; Michael Schulzer; Edwin Mak; Doris J Doudet; Raúl de la Fuente-Fernández
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-10       Impact factor: 9.236

6.  The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Authors:  Fulvio Bracco; Angelo Battaglia; Carlos Chouza; Erik Dupont; Oscar Gershanik; Jose Felix Marti Masso; Jean-Louis Montastruc
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.

Authors:  Rivka Inzelberg; Edna Schechtman; Puiu Nisipeanu
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Cabergoline : a review of its use in the treatment of Parkinson's disease.

Authors:  Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

Review 10.  Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies.

Authors:  Florian Krismer; Kurt A Jellinger; Sonja W Scholz; Klaus Seppi; Nadia Stefanova; Angelo Antonini; Werner Poewe; Gregor K Wenning
Journal:  Parkinsonism Relat Disord       Date:  2014-05-21       Impact factor: 4.891
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.